Vanguard Group Inc. grew its holdings in shares of BioSpecifics Technologies Corp. (NASDAQ:BSTC) by 0.5% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 277,233 shares of the biopharmaceutical company’s stock after acquiring an additional 1,320 shares during the quarter. Vanguard Group Inc. owned about 3.80% of BioSpecifics Technologies worth $16,554,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also modified their holdings of the company. Advisor Group Inc. boosted its position in shares of BioSpecifics Technologies by 94.2% during the 2nd quarter. Advisor Group Inc. now owns 734 shares of the biopharmaceutical company’s stock valued at $44,000 after acquiring an additional 356 shares during the last quarter. Advantage Investment Management LLC boosted its position in shares of BioSpecifics Technologies by 40.9% during the 2nd quarter. Advantage Investment Management LLC now owns 957 shares of the biopharmaceutical company’s stock valued at $57,000 after acquiring an additional 278 shares during the last quarter. Shaker Investments LLC OH bought a new stake in shares of BioSpecifics Technologies during the 2nd quarter valued at about $205,000. Sigma Planning Corp bought a new stake in shares of BioSpecifics Technologies during the 2nd quarter valued at about $263,000. Finally, Aperio Group LLC boosted its position in shares of BioSpecifics Technologies by 14.5% during the 2nd quarter. Aperio Group LLC now owns 4,496 shares of the biopharmaceutical company’s stock valued at $269,000 after acquiring an additional 571 shares during the last quarter. Hedge funds and other institutional investors own 59.08% of the company’s stock.

A number of analysts have recently issued reports on the company. HC Wainwright set a $90.00 price target on BioSpecifics Technologies and gave the company a “buy” rating in a research report on Friday, October 11th. BidaskClub downgraded BioSpecifics Technologies from a “sell” rating to a “strong sell” rating in a research report on Thursday. ValuEngine raised BioSpecifics Technologies from a “sell” rating to a “hold” rating in a report on Friday, October 4th. Finally, Zacks Investment Research cut BioSpecifics Technologies from a “buy” rating to a “hold” rating in a report on Friday.

Shares of NASDAQ BSTC traded down $0.56 during trading hours on Friday, reaching $48.78. 48,188 shares of the stock traded hands, compared to its average volume of 44,014. The company has a market capitalization of $361.68 million, a P/E ratio of 17.87 and a beta of 1.21. BioSpecifics Technologies Corp. has a 52-week low of $47.90 and a 52-week high of $73.31. The company’s 50-day simple moving average is $54.27 and its two-hundred day simple moving average is $59.64.

BioSpecifics Technologies (NASDAQ:BSTC) last announced its quarterly earnings data on Friday, August 9th. The biopharmaceutical company reported $0.87 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.72 by $0.15. The company had revenue of $8.85 million for the quarter, compared to analysts’ expectations of $8.98 million. BioSpecifics Technologies had a return on equity of 21.97% and a net margin of 63.06%. Analysts predict that BioSpecifics Technologies Corp. will post 3.17 earnings per share for the current year.

In related news, Director Toby Wegman sold 1,100 shares of the firm’s stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $55.23, for a total transaction of $60,753.00. Following the transaction, the director now directly owns 1,890 shares of the company’s stock, valued at approximately $104,384.70. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 16.39% of the company’s stock.

About BioSpecifics Technologies

BioSpecifics Technologies Corp., a biopharmaceutical company, engages in the development of an injectable collagenase clostridium histolyticum for various indications in the United States and internationally. The company offers injectable collagenase for the treatment of Dupuytren's contracture and Peyronie's disease under the XIAFLEX or Xiapex brands.

Featured Story: What is the S&P 500 Index?

Want to see what other hedge funds are holding BSTC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioSpecifics Technologies Corp. (NASDAQ:BSTC).

Institutional Ownership by Quarter for BioSpecifics Technologies (NASDAQ:BSTC)

Receive News & Ratings for BioSpecifics Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioSpecifics Technologies and related companies with MarketBeat.com's FREE daily email newsletter.